Compare HSBC Holdings plc (HSBC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Merck & Co., Inc. — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: HSBC Holdings plc and Merck & Co., Inc. are close in size by market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Merck & Co., Inc. for 98 Days on average.
| HSBC | MRK | |
|---|---|---|
Market Cap | $311.92B | $351.28B |
Volume | 3,546,658 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $107.86 | $156.43 |
52-Week Low | $65.67 | $82.49 |
Typical Hold Time | 36 Days | 98 Days |
Enterprise Value | $222.19B | $398.04B |
Dividend Yield | 4.05% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.61, down 1.17% over the past 24 hours, with technical indicators signaling a bearish trend. The company reported strong profitability with a net income margin of 34.54% and a P/E ratio of 13.23, reflecting reasonable valuation. Recent developments include expansion in technology banking and wealth management services, alongside strategic exits from non-core markets like Germany.
The outlook for HSBC is mixed; growth in wealth management and Asia presents opportunities, but bearish technicals and CFO transition in 2027 pose risks. Analyst sentiment is cautious with a majority hold rating, emphasizing the need for execution on strategic priorities to drive shareholder value amid global economic uncertainties.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
